Horizon Investments LLC Increases Stock Holdings in GSK plc (NYSE:GSK)

Horizon Investments LLC increased its stake in GSK plc (NYSE:GSK) by 2.7% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 17,206 shares of the pharmaceutical company’s stock after acquiring an additional 455 shares during the quarter. Horizon Investments LLC’s holdings in GSK were worth $582,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Dorsey & Whitney Trust CO LLC lifted its stake in GSK by 2.5% in the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 11,506 shares of the pharmaceutical company’s stock valued at $389,000 after buying an additional 278 shares in the last quarter. Sunbelt Securities Inc. raised its holdings in shares of GSK by 73.8% during the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock valued at $29,000 after acquiring an additional 302 shares during the last quarter. Rehmann Capital Advisory Group lifted its position in shares of GSK by 6.3% in the third quarter. Rehmann Capital Advisory Group now owns 5,608 shares of the pharmaceutical company’s stock valued at $232,000 after acquiring an additional 332 shares in the last quarter. GC Wealth Management RIA LLC boosted its stake in shares of GSK by 2.6% in the fourth quarter. GC Wealth Management RIA LLC now owns 14,009 shares of the pharmaceutical company’s stock worth $474,000 after acquiring an additional 353 shares during the last quarter. Finally, Jacobi Capital Management LLC increased its position in shares of GSK by 3.9% during the fourth quarter. Jacobi Capital Management LLC now owns 10,403 shares of the pharmaceutical company’s stock worth $352,000 after purchasing an additional 389 shares in the last quarter. 15.74% of the stock is currently owned by institutional investors and hedge funds.

GSK Stock Down 2.1 %

GSK opened at $39.53 on Thursday. GSK plc has a one year low of $31.72 and a one year high of $45.93. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78. The stock has a market capitalization of $81.81 billion, a P/E ratio of 24.86, a price-to-earnings-growth ratio of 1.12 and a beta of 0.58. The business’s 50-day simple moving average is $36.42 and its 200-day simple moving average is $36.98.

GSK (NYSE:GSK) last issued its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. Analysts anticipate that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be paid a dividend of $0.3932 per share. This represents a $1.57 dividend on an annualized basis and a dividend yield of 3.98%. This is a positive change from GSK’s previous quarterly dividend of $0.39. The ex-dividend date is Friday, February 21st. GSK’s payout ratio is 98.74%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. StockNews.com upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 7th. Morgan Stanley assumed coverage on shares of GSK in a report on Wednesday, February 12th. They issued an “equal weight” rating for the company. Seven analysts have rated the stock with a hold rating and four have given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.